DaShenLin Pharmaceutical Group Co., Ltd. (SHA:603233)

China · Delayed Price · Currency is CNY

16.15

+0.08 (0.50%)

Jun 18, 2026, 3:00 PM CST

1.25% (1Y)

Market Cap	18.39B -10.1%
Revenue (ttm)	27.52B +3.1%
Net Income	1.29B +31.8%
EPS	1.13 +30.8%
Shares Out	1.14B
PE Ratio	14.31
Forward PE	13.34
Dividend	0.98 (6.07%)
Ex-Dividend Date	n/a

Volume	5,794,947
Open	15.94
Previous Close	16.07
Day's Range	15.83 - 16.25
52-Week Range	15.34 - 21.78
Beta	0.54
Analysts	Buy
Price Target	24.49 (+51.64%)
Earnings Date	Aug 28, 2026

About SHA:603233

DaShenLin Pharmaceutical Group Co., Ltd. manufactures, distributes, and retails pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and antler tonic medicinal materials, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China. [Read more]

Industry Pharmaceutical Retailers

Sector Healthcare

Founded 1999

Employees 41,141

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603233

Full Company Profile

Financial Performance

In 2025, SHA:603233's revenue was 27.50 billion, an increase of 3.80% compared to the previous year's 26.50 billion. Earnings were 1.24 billion, an increase of 35.04%.

Financial Statements

Analyst Summary

According to 11 analysts, the average rating for 603233 stock is "Buy." The 12-month stock price target is ¥24.49, which is an increase of 51.64% from the latest price.

Price Target

¥24.49

(51.64% upside)

Analyst Consensus: Buy

Stock Forecasts